JOP20210110A1 - تحسين الأساليب الاصطناعية لإعداد مركبات حلقية متغايرة منصهرة كمُعدِّلات مستقبلات الأوريكسين - Google Patents

تحسين الأساليب الاصطناعية لإعداد مركبات حلقية متغايرة منصهرة كمُعدِّلات مستقبلات الأوريكسين

Info

Publication number
JOP20210110A1
JOP20210110A1 JOP/2021/0110A JOP20210110A JOP20210110A1 JO P20210110 A1 JOP20210110 A1 JO P20210110A1 JO P20210110 A JOP20210110 A JO P20210110A JO P20210110 A1 JOP20210110 A1 JO P20210110A1
Authority
JO
Jordan
Prior art keywords
orexin receptor
synthetic methods
heterocyclic compounds
receptor modulators
fused heterocyclic
Prior art date
Application number
JOP/2021/0110A
Other languages
English (en)
Inventor
Dinesh Gala
Dominique Paul Michel Depre
Kiran Matcha
Luc Jozef Raphael Moens
Andy Josephina Joannes Huygaerts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of JOP20210110A1 publication Critical patent/JOP20210110A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

وصف لعملية تحضير (((3aR,6aS)-5-(4,6-ثنائي ميثيل بيريميدين-2-يل)سداسي هيدروبيرولو[3,4-c]بيرول-2(1H)-يل)(2-فلورو-6-(2H-1,2,3-تريازول-2-يل)فينيل)ميثانون ، وهي عملية مفيدة للتصنيع التجاري. المركب المذكور عبارة عن مُعدِّل لمستقبل الأوركسين وربما يكون مفيدًا في التركيبات الصيدلانية وطرق علاج الحالات المرضية، والاضطرابات، والحالات التي يتوسطها نشاط الأوركسين، مثل الأرق والاكتئاب.
JOP/2021/0110A 2018-11-14 2019-11-11 تحسين الأساليب الاصطناعية لإعداد مركبات حلقية متغايرة منصهرة كمُعدِّلات مستقبلات الأوريكسين JOP20210110A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862760995P 2018-11-14 2018-11-14
PCT/IB2019/059677 WO2020100011A1 (en) 2018-11-14 2019-11-11 Improved synthetic methods of making fused heterocyclic compounds as orexin receptor modulators

Publications (1)

Publication Number Publication Date
JOP20210110A1 true JOP20210110A1 (ar) 2023-01-30

Family

ID=70730771

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0110A JOP20210110A1 (ar) 2018-11-14 2019-11-11 تحسين الأساليب الاصطناعية لإعداد مركبات حلقية متغايرة منصهرة كمُعدِّلات مستقبلات الأوريكسين

Country Status (25)

Country Link
US (1) US12030887B2 (ar)
EP (2) EP4428136A2 (ar)
JP (1) JP7398452B2 (ar)
KR (1) KR20210091726A (ar)
CN (1) CN113038952B (ar)
AR (1) AR117074A1 (ar)
AU (1) AU2019380072A1 (ar)
BR (1) BR112021009211A2 (ar)
CA (1) CA3118734A1 (ar)
CR (1) CR20210240A (ar)
EA (1) EA202191356A1 (ar)
EC (1) ECSP21034253A (ar)
HR (1) HRP20240743T1 (ar)
HU (1) HUE066708T2 (ar)
IL (1) IL283067A (ar)
JO (1) JOP20210110A1 (ar)
MA (1) MA54250A (ar)
MX (1) MX2021005698A (ar)
PE (1) PE20211470A1 (ar)
PH (1) PH12021551054A1 (ar)
PL (1) PL3880204T3 (ar)
RS (1) RS65638B1 (ar)
SG (1) SG11202104886YA (ar)
TW (1) TW202039452A (ar)
WO (1) WO2020100011A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022194122A1 (zh) * 2021-03-16 2022-09-22 上海翰森生物医药科技有限公司 含氮杂环的多环化合物及其制备方法和应用
TW202416988A (zh) * 2022-09-14 2024-05-01 大陸商江蘇豪森藥業集團有限公司 含氮雜環的多環化合物的游離鹼晶型及其製備方法
WO2024125395A1 (zh) * 2022-12-12 2024-06-20 江苏恩华药业股份有限公司 一种取代四氢环戊基[c]吡咯衍生物、制备方法、中间体及其应用
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4341403A1 (de) 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US20060258691A1 (en) 2005-05-13 2006-11-16 Joseph Barbosa Methods and compositions for improving cognition
BRPI0611439A2 (pt) 2005-05-13 2010-09-08 Lexicon Pharmaceuticals Inc compostos multicìclicos e métodos para uso dos mesmos
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
EP2089018A2 (en) 2006-11-07 2009-08-19 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
EP2235010A1 (en) 2007-12-21 2010-10-06 AstraZeneca AB Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
US9062044B2 (en) 2009-10-23 2015-06-23 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
MX2012004753A (es) * 2009-10-23 2012-09-07 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina.
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
WO2015150252A1 (en) 2014-04-01 2015-10-08 Bayer Cropscience Ag Use of heterocyclic compounds for controlling nematodes
US9938276B2 (en) * 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
JP6698633B2 (ja) * 2015-04-24 2020-05-27 武田薬品工業株式会社 複素環化合物
HUE058759T2 (hu) 2016-03-10 2022-09-28 Janssen Pharmaceutica Nv Módszerek depresszió kezelésére orexin-2 receptor antagonisták alkalmazásával
GB201702174D0 (en) 2017-02-09 2017-03-29 Benevolentai Bio Ltd Orexin receptor antagonists

Also Published As

Publication number Publication date
MX2021005698A (es) 2021-07-07
US12030887B2 (en) 2024-07-09
AR117074A1 (es) 2021-07-07
CA3118734A1 (en) 2020-05-22
EP4428136A2 (en) 2024-09-11
EP3880204C0 (en) 2024-05-15
MA54250A (fr) 2022-02-23
AU2019380072A1 (en) 2021-05-27
JP7398452B2 (ja) 2023-12-14
EP3880204A4 (en) 2022-08-17
US20220009932A1 (en) 2022-01-13
TW202039452A (zh) 2020-11-01
PL3880204T3 (pl) 2024-09-09
RS65638B1 (sr) 2024-07-31
KR20210091726A (ko) 2021-07-22
EA202191356A1 (ru) 2021-08-11
WO2020100011A1 (en) 2020-05-22
ECSP21034253A (es) 2021-06-30
PE20211470A1 (es) 2021-08-05
CN113038952A (zh) 2021-06-25
JP2022507361A (ja) 2022-01-18
CR20210240A (es) 2021-06-08
BR112021009211A2 (pt) 2021-08-03
IL283067A (en) 2021-06-30
PH12021551054A1 (en) 2021-12-06
EP3880204A1 (en) 2021-09-22
HUE066708T2 (hu) 2024-09-28
SG11202104886YA (en) 2021-06-29
CN113038952B (zh) 2024-08-23
EP3880204B1 (en) 2024-05-15
HRP20240743T1 (hr) 2024-08-30

Similar Documents

Publication Publication Date Title
PH12021551054A1 (en) Improved synthetic methods of making fused heterocyclic compounds as orexin receptor modulators
MX2021011438A (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak.
SV2018005800A (es) Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
WO2009003669A3 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
MX2022004474A (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak.
MX2018000718A (es) Macrociclos de diarilo quirales y usos de los mismos.
NZ630719A (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
WO2011149950A3 (en) Bicyclic heteroaryl kinase inhibitors and methods of use
MX2010009458A (es) Derivados biciclicos heterociclicos o espirobiciclicos heterociclicos enlazados, de pirazolo[1,5-a]pirimidinas, procedimientos para su preparacion y usos de los mismos.
MX2019005154A (es) Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2.
MX2021015510A (es) Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b.
SA520412192B1 (ar) مشتقات 5-(2-(2، 5-داي فلورو فنيل)بيروليدين-1-يل) -3-(1h-بيرازول-1-يل) بيرازولو[1، 5-a] بيريميدين والمركبات ذات الصلة كمثبطات كيناز trk لعلاج السرطان
MX2020009586A (es) Compuestos de (2-azabiciclo[3.1.0]hexan-2-il)pirazolo[1,5-a]pirimi dina e imidazo[1,2-b]piridazina sustituidos como inhibidores de cinasas trk.
EP3825317A3 (en) Process for preparing btk inhibitors
PH12020551984A1 (en) Small molecule inhibitors of the jak family of kinases
BR112018013763A2 (pt) moduladores alostéricos positivos do receptor muscarínico de acetilclona m4
MX2019005123A (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2.
PE20212196A1 (es) Compuestos, composiciones, y metodos para modular la actividad cdk9
MX2019005115A (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2.
MX2023004942A (es) Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.
JOP20220031A1 (ar) أساليب اصطناعية مُحسَّنة لإعداد مركبات (2h-1,2,3-تريازول-2-يل) فينيل كمُعدِّلات لمستقبلات الأوريكسين
MX2022011310A (es) Azabiciclo y derivados de diazepina para tratar trastornos oculares.
MX2024005884A (es) Usos de compuestos biciclicos para el tratamiento de enfermedades.
EA202190047A1 (ru) Низкомолекулярные ингибиторы киназ семейства jak